Editorial
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Nov 27, 2023; 15(11): 1170-1173
Published online Nov 27, 2023. doi: 10.4254/wjh.v15.i11.1170
Editorial: Metabolomics in chronic hepatitis C: Decoding fibrosis grading and underlying pathways
Jorge Quarleri, M Victoria Delpino
Jorge Quarleri, M Victoria Delpino, Instituto de Investigaciones Biomédicas en Retrovirus y Sida, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires 1121, Argentina
Author contributions: Quarleri J and Delpino MV contributed equally to this work. Both authors have read and approved the final manuscript.
Supported by National Scientific and Technical Research Council, No. PICT-2020-01173; No. PICT-2019-1698, No. PICT2019-00499, and No. PICT-2020-00691; CONICET, No. PIP 2021-11220200101476CO.
Conflict-of-interest statement: The authors disclose no financial conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jorge Quarleri, PhD, Adjunct Professor, Research Scientist, Instituto de Investigaciones Biomédicas en Retrovirus y Sida, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas Técnicas, No. 2155 Paraguay, Buenos Aires 1121, Argentina. quarleri@fmed.uba.ar
Received: October 24, 2023
Peer-review started: October 24, 2023
First decision: November 7, 2023
Revised: November 7, 2023
Accepted: November 13, 2023
Article in press: November 13, 2023
Published online: November 27, 2023
Processing time: 30 Days and 15.8 Hours
Core Tip

Core Tip: Accurate diagnosis of liver damage in chronic hepatitis C is pivotal for decision-making. Liver biopsy, the traditional "gold standard" for assessing tissue damage, offers valuable insights but is invasive, with potential complications and sampling errors. Non-invasive methods have made progress in the last decade, but challenges remain. Various non-invasive techniques are in development, including serum biomarker assays and advanced imaging. They often struggle to distinguish intermediate fibrosis stages and are affected by hepatic and extrahepatic factors. This Editorial discusses which identified potential biomarkers in plasma samples linked to each fibrosis grade and hepatitis C virus-induced pathogenesis.